The Waltham, Mass.-based company said that the new system is intended to allow for simpler operation and maintenance with additional treatment options, and added that the system features a number of newly automated technologies.
“The new and enhanced 2008T BlueStar hemodialysis machines provide more than 30 unique enhancements to better serve end stage renal disease patients undergoing dialysis. Our new machines represent a significant step forward for providers and patients who depend upon our life-sustaining technologies and an exciting continuation of our 30-year commitment to the treatment of end stage renal disease,” Fresenius Medical Care NA renal therapies group prez Mark Costanzo said in a prepared statement.
The newly launched dialysis system features auto-start and auto-prime features, as well as assisted reinfusion, Fresenius Medical Care said. The device also features an idle mode to reduce dialysate and water usage, independent conductivity and pH self-testing, a disinfection log, patient cards and low volume therapy treatment capabilities.
“Leveraging our history of innovation and industry firsts in renal care, we are pleased to unveil new features that will help providers deliver the highest quality of care to patients receiving hemodialysis both in-center and in the acute care setting. We believe our 2008T BlueStar machine offers distinct clinical advantages that streamline the complexities of hemodialysis care and enhance patients’ overall treatment experience,” Fresenius Medical Care NA renal therapies group chief medical officer Dr. Robert Kossmann said in a press release.
In late January, Fresenius said that an interruption to the FTC’s review of its merger with NxStage Medical (NSDQ:NXTM), caused by the partial U.S. government shutdown, has again delayed the end-date of the deal which has now been extended to August 6, 2019.